Macrocyclic lactone compounds and methods for their use

Details Macrocyclic lactone compounds and methods for their use Macrocyclic lactone compounds and methods for their use

2011-01-11

2011-01-11

Ha, Julie (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S019200, C514S172000, C514S211110, C424S423000

Reexamination Certificate

active

07867988

ABSTRACT:
A method of inhibiting smooth muscle cell proliferation or cytokine production in a subject, comprising administering a compound disclosed herein to the subject, is provided. The compound can be administered systemically, locally, or a combination thereof. For example, the compound can be locally delivered from a temporary device or an implant, such as a vascular prosthesis.

REFERENCES:
patent: 3929992 (1975-12-01), Sehgal et al.
patent: 5646160 (1997-07-01), Morris et al.
patent: 5665772 (1997-09-01), Cottens et al.
patent: 5728710 (1998-03-01), Luego
patent: 5957975 (1999-09-01), Lafont et al.
patent: 5985890 (1999-11-01), Cottens et al.
patent: 6001998 (1999-12-01), Nishida et al.
patent: 6015815 (2000-01-01), Mollison
patent: 6187568 (2001-02-01), Nishida et al.
patent: 6273913 (2001-08-01), Wright et al.
patent: 6585764 (2003-07-01), Wright et al.
patent: 6641611 (2003-11-01), Jayaraman
patent: 6805703 (2004-10-01), McMorrow
patent: 7025734 (2006-04-01), Ellis et al.
patent: 7056942 (2006-06-01), Hildesheim et al.
patent: 2001/0027340 (2001-10-01), Wright et al.
patent: 2001/0029351 (2001-10-01), Falotico et al.
patent: 2002/0005206 (2002-01-01), Falotico et al.
patent: 2002/0007213 (2002-01-01), Falotico et al.
patent: 2002/0082680 (2002-06-01), Shanley et al.
patent: 2002/0123505 (2002-09-01), Mollison et al.
patent: 2004/0072857 (2004-04-01), Waugh et al.
patent: 2005/0033417 (2005-02-01), Borges et al.
patent: 2005/0152842 (2005-07-01), Li et al.
patent: 2005/0208095 (2005-09-01), Hunter et al.
patent: 2005/0209244 (2005-09-01), Prescott et al.
patent: 2005/0239178 (2005-10-01), Ruppen et al.
patent: 2006/0229711 (2006-10-01), Yan et al.
patent: 2007/0015697 (2007-01-01), Peyman
patent: 2007/0059336 (2007-03-01), Hughes et al.
patent: 2007/0207186 (2007-09-01), Scanlon et al.
patent: 2008/0086198 (2008-04-01), Owens et al.
patent: 1236478 (2002-09-01), None
patent: WO 93/16189 (1993-08-01), None
patent: WO 94/09010 (1994-04-01), None
patent: WO 96/41807 (1996-12-01), None
patent: WO 98/07415 (1998-02-01), None
patent: WO 01/87263 (2001-11-01), None
patent: WO 01/87342 (2001-11-01), None
patent: WO 01/87372 (2001-11-01), None
patent: WO 01/87373 (2001-11-01), None
patent: WO 01/87374 (2001-11-01), None
patent: WO 01/87375 (2001-11-01), None
patent: WO 01/87376 (2001-11-01), None
patent: WO 02/056790 (2002-07-01), None
patent: WO 02/065947 (2002-08-01), None
patent: WO 2006/116716 (2006-11-01), None
Cell proliferation definition from http://www.cancer.gov/Templates/db—alpha.aspx?CdrID=46479), p. 1. Accessed Jul. 28, 2009.
Introduction to Cancer from Merck manual, p. 1. Accessed Mar. 5, 2008.
Clinical Aspects of Cancer from Merck manual, pp. 1-4. Accessed Mar. 5, 2008.
Auerbach R, Akhtar N, Lewis RL, Shinners BL, “Angiogenesis assays: Problems and pitfalls,” Cancer and Metastasis Reviews, 2000, 19: 167-172.
Gura T, “Systems for Identifying New Drugs are Often Faulty,” Science, 1997, 278(7): 1041-1042.
Jain RK, “Barriers to Drug Delivery in Solid Tumors,” Scientific American, Jul. 1994, 58-65.
Kaposi's Sarcoma from Merck manual, pp. 1-3. Accessed Jun. 1, 2009.
Bowen's Disease from Merck manula, p. 1. Accessed Jun. 1, 2009.
Squamous Cell Carcinoma from Merck manual, pp. 1-2. Accessed Jun. 1, 2009.
Rheumatoid Arthritis from Merck manual, pp. 1-11. Accessed Jul. 29, 2009.
Introduction to Asthma from Merck manual, pp. 1-14. Accessed Jul. 28, 2009.
Definition of inhibit from www.dictionary.com, pp. 1-3. Accessed Jul. 29, 2009.
Definition of isomer from http://www.answers.com/topic/isomer, pp. 1-10. Accessed Jul. 29, 2009.
Hensley S, “Zyrtec Looks in Mirror and Sees Xyzal,” from http://blogs.wsj.com/health/2007/05/29/zyrtec-looks-in-mirror-and-sees-xyzal/, pp. 1-3. Accessed Jul. 29, 2009.
More D, “Xyzal: Stateof the Art Antihistamine,” p. 1, Accessed Jul. 29, 2009.
Chirality and Thalidomide from http://www/skingenious.com/faq.html, pp. 1-7. Accessed Jul. 29, 2009.
Han H-Y, “Targeted Prodrug Design to Optimize Drug Delivery,” AAPS Pharmsci, 2000, 2(1): 1-11.
Vippagunta SR, Brittain HG, Grant DJW, “Crystalline Solids,” Advanced Drug Delivery Reviews, 2001, 48: 3-26.
“Drug-Coated Stent Blocks Restenosis; Brief Article,” Marketletter, p. N/A, 0951-3175 (2000)—IAC-ACC-No. 68770167.
Marx et al., “Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells,” 1995, Circ. Res., vol. 76, No. 3, pp. 412-417.
Morice et al., “A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization,” 2002, N. Engl. J. Med., vol. 346, No. 23, pp. 1773-1780.
Poon et al., “Rapamycin inhibits vascular smooth muscle cell migration,” 1996, J. Clin. Invest., vol. 98, pp. 2277-2283.
Simonsen et al., “Cardiology Market Continues Rapid Growth on a Broad Technology Front,” The BBI Newsletter, vol. 22, No. 4, p. 73, 1049-4316 (1999).
Sousa et al., “Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents: One-Year Angiographic and Intravascular Ultrasound Follow-Up,” 2001, Circulation, vol. 104, No. 17, pp. 2007-2011.
Suzuki et al., “Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model,” 2001, Circulation, vol. 104, pp. 1188-1193.
Vignot et al. “mTOR-targeted therapy of cancer with rapamycin derivatives,” 2005, Annals of Oncology, 16, pp. 525-537.
Cai et al., “In Vitro Metabolic Study of Temsirolimus: Preparation, Isolation, and Identification of the Metabolites,” DMD. Sep. 2007; 35 (9):1554-1563.
Dupont et al., “The Evolving Role of Sirolimus in Renal Transplantation,” QJMed. 2003; 96(6):401-409.
Edwards et al., “The Rapamycin-binding Domain of the Protein Kinase Mammalian Target of Rapamycin Is a Destabilizing Domain*,” JBC. May 4, 2007; 282(18):13395-13401; retrieved from the Internet: <http://wandless.stanford.edu/documents/2-tjwPDFs/TJW38.pdf>.
Fingar et al, “Target of Rapamycin (TOR): an Integrator of Nutrient and Growth Factor Signals and Coordinator of Cell Growth and Cell Cycle Progression,” Oncogene. Apr. 19, 2004;23(18):3151-3171.
Gallant-Haidner et al., “Pharmacokinetics and Metabolism of Sirolimus,” Therapeutic Drug Monitoring. Feb. 2000; 22 (1):31-35.
Grinfeld et al., “Acid Catalyzed Functionalization of Rapamycin,” Tetrahedron Letters. Sep. 12, 1994; 35(37):6835-6838.
Hultsch et al., “The Effect of the Immunophilin Ligands Rapamycin and FK506 on Proliferation of Mast Cells and Other Hematopoietic Cell Lines,” Mol Biol Cell. Sep. 1992; 3(9): 981-987.
Kuhnt et al., “Microbial Conversion of Rapamycin,” Enzyme and Microbial Technology. Nov. 1, 1997; 21(6):405-412.
Leung et al., “Pharmacokinetics and Metabolic Disposition of Sirolimus in Healthy Male Volunteers After a Single Oral Dose,” Ther Drug Monit. Feb. 2006;28(1):51-61.
Luengo et al., “Structure-Activity Studies of Rapamycin Analogs: Evidence that the C-7 Methoxy Group is Part of the Effector Domain and Positioned at the FKBP12-FRAP Interface,” Chemistry & Biology. Jul. 1995; 2(7):471-481.
Onuma et al., “Mahoroba, First-In-Man Study: 6-Month Results of a Biodegradable Polymer Sustained Release Tacrolimus-Eluting Stent in de novo Coronary Stenoses,” Eur Heart J. 2009; 30(12):1477-1485; retrieved from the Internet: <http://eurheartj.oxfordjournals.org/content/30/12/1477.full.pdf+html>.
Trepanier et al., “Rapamycin: Distribution, Pharmacokinetics and Therapeutic Range Investigations: An Update,” Clin Biochem. Jul. 1998;31(5):345-351.

Affiliated with

Also associated with

Rating

Macrocyclic lactone compounds and methods for their use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Macrocyclic lactone compounds and methods for their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Macrocyclic lactone compounds and methods for their use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2690653